Search Results - "Taus, Luke J"

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity by Mahadevan, Navin R, Knelson, Erik H, Wolff, Jacquelyn O, Vajdi, Amir, Saigí, Maria, Campisi, Marco, Hong, Deli, Thai, Tran C, Piel, Brandon, Han, Saemi, Reinhold, Bruce B, Duke-Cohan, Jonathan S, Poitras, Michael J, Taus, Luke J, Lizotte, Patrick H, Portell, Andrew, Quadros, Victor, Santucci, Alison D, Murayama, Takahiko, Cañadas, Israel, Kitajima, Shunsuke, Akitsu, Aoi, Fridrikh, Maya, Watanabe, Hideo, Reardon, Brendan, Gokhale, Prafulla C, Paweletz, Cloud P, Awad, Mark M, Van Allen, Eliezer M, Lako, Ana, Wang, Xi-Tao, Chen, Benjamin, Hong, Fangxin, Sholl, Lynette M, Tolstorukov, Michael Y, Pfaff, Kathleen, Jänne, Pasi A, Gjini, Evisa, Edwards, Robin, Rodig, Scott, Reinherz, Ellis L, Oser, Matthew G, Barbie, David A

“…Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity,…”
Get more information

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade by Sehgal, Kartik, Portell, Andrew, Ivanova, Elena V, Lizotte, Patrick H, Mahadevan, Navin R, Greene, Jonathan R, Vajdi, Amir, Gurjao, Carino, Teceno, Tyler, Taus, Luke J, Thai, Tran C, Kitajima, Shunsuke, Liu, Derek, Tani, Tetsuo, Noureddine, Moataz, Lau, Christie J, Kirschmeier, Paul T, Liu, David, Giannakis, Marios, Jenkins, Russell W, Gokhale, Prafulla C, Goldoni, Silvia, Pinzon-Ortiz, Maria, Hastings, William D, Hammerman, Peter S, Miret, Juan J, Paweletz, Cloud P, Barbie, David A

“…Resistance to oncogene-targeted therapies involves discrete drug-tolerant persister cells, originally discovered through in vitro assays. Whether a similar…”
Get full text

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance by Bahcall, Magda, Paweletz, Cloud P, Kuang, Yanan, Taus, Luke J, Sim, Taebo, Kim, Nam Doo, Dholakia, Kshiti H, Lau, Christie J, Gokhale, Prafulla C, Chopade, Pratik R, Hong, Fangxin, Wei, Zihan, Köhler, Jens, Kirschmeier, Paul T, Guo, Jiannan, Guo, Sujuan, Wang, Stephen, Jänne, Pasi A

“…MET-targeted therapies are clinically effective in -amplified and exon 14 deletion mutant ( ex14) non-small cell lung cancers (NSCLCs), but their efficacy is…”
Get full text

Quantification of metastatic load in a syngeneic murine model of metastasis by Taus, Luke J., Flores, Roberto E., Seyfried, Thomas N.

“…Bioluminescence imaging (BLI) is an established method for evaluating metastatic load in preclinical cancer models; however, BLI can produce observational…”
Get full text

Abstract 5543: TAK1 deficiency in tumor cells enhances sensitivity to CTL-mediated killing via TNF-α by Miret, Juan J., Luster, Troy A., Lizotte, Patrick, Wu, Min, Nzikoba, Sarah, Taus, Luke Taus J., Gokhale, Prafulla C., Kirschmeier, Paul, Barbie, David, Paweletz, Cloud P.

“…Abstract The clinical successes achieved by different immunotherapies have resulted in a paradigm shift in treatment modalities. Despite these significant…”
Get full text

Abstract 1483: Ex vivo single cell RNA-sequencing of tumor derived organotypic spheroids identifies a unique mesenchymal resistance program to PD-1 blockade by Portell, Andrew J., Greene, Jonathan, Taus, Luke J., Lizotte, Patrick, Ivanova, Elena, Menezes, Kalil O., Aref, Amir R., Kirschmeier, Paul, Jenkins, Russell W., Barbie, David, Paweletz, Cloud P.

“…Abstract Introduction: Immune checkpoint blockade, including αPD-1 and αPD-L1 form the backbone of personalized medicine for lung cancer and other…”
Get full text

Abstract 4806: Exploring optimal targeted combination therapies with neratinib for HER2 mutated NSCLC by Kuraguchi, Mari, Taus, Luke J., Zhou, Shan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Kirschmeier, Paul, Jänne, Pasi A.

“…Abstract Genetic alterations which constitutively activate human epidermal growth factor receptor 2 (HER2; ERBB2) without overexpression have been observed in…”
Get full text

Abstract 4935: High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing by Lizotte, Patrick H., Luster, Troy, Cavanaugh, Megan E., Taus, Luke J., Dhaneshwar, Abha, Mayman, Naomi, Yang, Aaron, Bittinger, Mark, Kirschmeier, Paul, Gray, Nathanael S., Barbie, David A., Janne, Pasi A.

“…Abstract As immune checkpoint blocking antibodies increasing become foundational therapies for the treatment of cancer, there is a pressing need to identify…”
Get full text